Verrica Pharmaceuticals Inc (NASDAQ:VRCA) has a beta value of 1.37 and has seen 1.35 million shares traded in the last trading session. The company, currently valued at $50.62M, closed the last trade at $1.11 per share which meant it gained $0.12 on the day or 12.01% during that session. The VRCA stock price is -927.93% off its 52-week high price of $11.41 and 36.94% above the 52-week low of $0.70. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.65 million shares traded. The 3-month trading volume is 956.38K shares.

The consensus among analysts is that Verrica Pharmaceuticals Inc (VRCA) is Buy stock at the moment, with a recommendation rating of 2.60. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) trade information

Sporting 12.01% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the VRCA stock price touched $1.11 or saw a rise of 3.48%. Year-to-date, Verrica Pharmaceuticals Inc shares have moved -84.84%, while the 5-day performance has seen it change 24.72%. Over the past 30 days, the shares of Verrica Pharmaceuticals Inc (NASDAQ:VRCA) have changed -28.85%. Short interest in the company has seen 4.37 million shares shorted with days to cover at 4.35.

Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 90.75% from current levels. The projected low price target is $10.0 while the price target rests at a high of $14.0. In that case, then, we find that the current price level is -1161.26% off the targeted high while a plunge would see the stock gain -800.9% from current levels.

Verrica Pharmaceuticals Inc (VRCA) estimates and forecasts

Figures show that Verrica Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -86.83% over the past 6 months, with this year growth rate of -24.56%, compared to 16.70% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -0.97% over the past 5 years.

VRCA Dividends

Verrica Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA)’s Major holders

Insiders own 16.20% of the company shares, while shares held by institutions stand at 16.50% with a share float percentage of 19.68%. Investors are also buoyed by the number of investors in a company, with Verrica Pharmaceuticals Inc having a total of 100.0 institutions that hold shares in the company. The top two institutional holders are PERCEPTIVE ADVISORS LLC with over 7.1 million shares worth more than $51.75 million. As of 2024-06-30, PERCEPTIVE ADVISORS LLC held 15.2724% of shares outstanding.

The other major institutional holder is AVORO CAPITAL ADVISORS LLC, with the holding of over 4.0 million shares as of 2024-06-30. The firm’s total holdings are worth over $29.16 million and represent 8.6052% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology . As of Jun 30, 2024 , the former fund manager holds about 1.79% shares in the company for having 815.89 shares of worth $0.91 million while later fund manager owns 629.87 shares of worth $0.7 million as of Sep 30, 2024 , which makes it owner of about 1.38% of company’s outstanding stock.